Victory Capital Management Inc. Has $27.43 Million Holdings in Zoetis Inc. $ZTS

Victory Capital Management Inc. trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 88.1% in the third quarter, HoldingsChannel reports. The firm owned 187,489 shares of the company’s stock after selling 1,382,837 shares during the period. Victory Capital Management Inc.’s holdings in Zoetis were worth $27,433,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ZTS. Norges Bank bought a new stake in shares of Zoetis during the second quarter worth $809,491,000. Diamond Hill Capital Management Inc. acquired a new position in Zoetis during the 3rd quarter worth about $394,010,000. Corient Private Wealth LLC grew its holdings in Zoetis by 85.9% during the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after acquiring an additional 1,191,840 shares during the last quarter. Impax Asset Management Group plc increased its position in Zoetis by 362.6% in the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after acquiring an additional 922,589 shares in the last quarter. Finally, Swedbank AB increased its position in Zoetis by 60.4% in the 3rd quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock valued at $356,565,000 after acquiring an additional 917,598 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $121.54 on Monday. The company has a fifty day moving average price of $126.06 and a two-hundred day moving average price of $132.88. The firm has a market capitalization of $51.31 billion, a PE ratio of 20.19, a P/E/G ratio of 1.85 and a beta of 0.95. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.00. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue was up 3.0% on a year-over-year basis. During the same period last year, the company earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. KeyCorp initiated coverage on shares of Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. Barclays started coverage on shares of Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. HSBC set a $140.00 price objective on Zoetis in a research report on Wednesday, December 10th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.